Mainz Biomed (MYNZ) Competitors

Senti Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 790.99%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Senti Biosciences is more favorable than Mainz Biomed.

Mainz Biomed's return on equity of 0.00% beat Senti Biosciences' return on equity.

In the previous week, Senti Biosciences had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Mainz Biomed. Senti Biosciences' average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

Mainz Biomed has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

25.7% of Senti Biosciences shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Senti Biosciences has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

Mainz Biomed has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

19.0% of Celularity shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

In the previous week, Celularity had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Celularity and 0 mentions for Mainz Biomed. Celularity's average media sentiment score of 0.20 beat Mainz Biomed's score of 0.00 indicating that Celularity is being referred to more favorably in the news media.

Celularity has a consensus price target of $6.00, suggesting a potential upside of 536.94%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Mainz Biomed.

Mainz Biomed has a net margin of 0.00% compared to Celularity's net margin of -198.75%.

Mainz Biomed has higher revenue and earnings than Oncobiologics. Oncobiologics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

11.2% of Oncobiologics shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 2.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500.

In the previous week, Oncobiologics had 4 more articles in the media than Mainz Biomed. MarketBeat recorded 4 mentions for Oncobiologics and 0 mentions for Mainz Biomed. Oncobiologics' average media sentiment score of 1.00 beat Mainz Biomed's score of 0.00 indicating that Oncobiologics is being referred to more favorably in the news media.

Oncobiologics has a consensus price target of $4.50, suggesting a potential upside of 1,761.81%. Given Oncobiologics' stronger consensus rating and higher possible upside, analysts clearly believe Oncobiologics is more favorable than Mainz Biomed.

28.0% of Dyadic International shares are held by institutional investors. 29.5% of Dyadic International shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dyadic International has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.

In the previous week, Dyadic International had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Dyadic International and 0 mentions for Mainz Biomed. Dyadic International's average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

Mainz Biomed has a net margin of 0.00% compared to Dyadic International's net margin of -239.67%. Mainz Biomed's return on equity of 0.00% beat Dyadic International's return on equity.

Dyadic International has higher revenue and earnings than Mainz Biomed. Dyadic International is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Dyadic International presently has a consensus price target of $3.00, suggesting a potential upside of 287.05%. Given Dyadic International's stronger consensus rating and higher probable upside, equities analysts clearly believe Dyadic International is more favorable than Mainz Biomed.